8th June 2022. Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Carl Hvass as its Chief Financial Officer (CFO).
Carl brings with him a wealth of experience after having held senior finance positions for most of his career, most recently within the CRO industry as Group Financial Controller at Ergomed Plc and before this at Chiltern International Limited.
Carl will be responsible for the financial function across Bionical Emas, which includes cash flow management, assessing and strengthening the financial controls and overseeing all aspects of the Group’s financial success, reporting into CEO, Jonathan Waring-Hughes. He joins the Executive Leadership Team.
Carl is a Fellow of the Institute of Chartered Accountants in England and Wales (ICAEW).
We are delighted to welcome Carl to the company as we move through to the next phase of our exciting growth and expansion. He brings a wealth of sector-specific knowledge and experience having held senior financial positions at various PE backed and AIM listed CRO’s.
Carl’s deep understanding of the clinical research sector will enable us to improve our financial modelling and forecasting for future success, as well as ensuring we are well positioned to fund our future growth strategies.Jonathan Waring-Hughes, Chief Executive Officer at Bionical Emas
Katie Clayton, Head of Marketing
+44 (0) 1462 416435
Adrian Duffield, Managing Director
+44 (0) 7990 85 85 48
Note to Editors
Bionical Emas (bionicalemas.com) is a Contract Research Organisation (CRO) which combines Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to deliver a unique, seamless approach to pioneering the way life-changing medicines are developed and accessed for patients around the world.
The Group deliver full clinical development services to global pharma and biotech companies. It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway.
Bionical Emas runs global programs, employs 250 people, and has offices in US, Europe, and Australia. It serves 10 of the top 25 pharma companies.